公开(公告)号：US20090234586A1

公开(公告)日：2009-09-17

申请号：US12365270

申请日：2009-02-04

申请人： Takayuki TANAKA ,  Yukio NIHEI ,  Toshihiko ANDO ,  Minoru YAMAKADO ,  Keita TAKAMATSU ,  Eiko TAKAHASHI ,  Norio SASAMORI

发明人： Takayuki TANAKA ,  Yukio NIHEI ,  Toshihiko ANDO ,  Minoru YAMAKADO ,  Keita TAKAMATSU ,  Eiko TAKAHASHI ,  Norio SASAMORI

IPC分类号： G06F19/00 ,  G06F17/18

CPC分类号： G01N33/6812 ,  G01N2800/304 ,  G06F19/18 ,  G06F19/24 ,  G06F19/28

摘要： According to the method of evaluating stress of the present invention, amino acid concentration data on the concentration value of amino acid in blood collected from a subject to be evaluated is measured, and a stress state including at least depressive illness and major depressive illness in the subject is evaluated based on the concentration value of at least one of Lys, His, ABA, Asn, Phe, Leu, Ile, Val, Trp, Tyr and Met contained in the measured amino acid concentration data of the subject.

摘要翻译： 根据本发明的应力评价方法，测定从评价对象收集的血液中的氨基酸浓度值的氨基酸浓度数据，并且测定包含至少抑郁症和重度抑郁症的应激状态 基于测定的受试者的氨基酸浓度数据中所含的Lys，His，ABA，Asn，Phe，Leu，Ile，Val，Trp，Tyr和Met中的至少一种的浓度值进行评估。

公开(公告)号：US20100216755A1

公开(公告)日：2010-08-26

申请号：US12774912

申请日：2010-05-06

申请人： Yukio NIHEI ,  Yoshihiro Morinaga ,  Manabu Suzuki ,  Yasuyo Suga

发明人： Yukio NIHEI ,  Yoshihiro Morinaga ,  Manabu Suzuki ,  Yasuyo Suga

IPC分类号： A61K31/567 ,  A61P35/00

CPC分类号： A61K31/05 ,  A61K31/167 ,  A61K31/573 ,  A61K45/06 ,  A61K2300/00

摘要： The present application provides a method for the treatment of tumors where the lethal dose of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is increased to twice or more, the toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, gastrointestinal toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, hepatic toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, and/or cardiovascular toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, by administering to a subject in need thereof a composition containing: (a) an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone; and (b) (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or a salt thereof.

摘要翻译： 本申请提供了一种治疗肿瘤的方法，其中致死剂量的（Z）-N- [2-甲氧基-5- [2-（3,4,5-三甲氧基苯基）乙烯基]苯基] -L-丝氨酰胺是 （Z）-N- [2-甲氧基-5- [2-（3,4,5-三甲氧基苯基）乙烯基]苯基] -L-丝氨酰胺的药学有效剂量的毒性降低至两倍以上， 在（Z）-N- [2-甲氧基-5- [2-（3,4,5-三甲氧基苯基）乙烯基]苯基] -L-丝氨酰胺的药学有效剂量下，胃肠道毒性降低，药物有效 （Z）-N- [2-甲氧基-5- [2-（3,4,5-三甲氧基苯基）乙烯基]苯基] -L-丝氨酰胺的剂量和/或心血管毒性在药学有效剂量 Z）-N- [2-甲氧基-5- [2-（3,4,5-三甲氧基苯基）乙烯基]苯基] -L-丝氨酰胺通过向有需要的受试者施用包含以下物质的组合物：（a） 有效量的抗炎活性物质，其中所述抗炎活性物质为 选自地塞米松，地塞米松的酯和地塞米松的盐的地塞米松; 和（b）（Z）-N- [2-甲氧基-5- [2-（3,4,5-三甲氧基苯基）乙烯基]苯基] -L-丝氨酰胺或其盐。